Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,771 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.
Barco S, Granziera S, Coppens M, Douxfils J, Nijkeuter M, Riva N, Vanassche T, Zhang G, Lin M, Kamphuisen PW, Cohen AT, Beyer-Westendorf J. Barco S, et al. Among authors: lin m. Thromb Haemost. 2019 Apr;119(4):675-684. doi: 10.1055/s-0039-1678546. Epub 2019 Feb 7. Thromb Haemost. 2019. PMID: 30731492 Clinical Trial.
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Chan MY, et al. Among authors: lin m. Circulation. 2008 Jun 3;117(22):2865-74. doi: 10.1161/CIRCULATIONAHA.107.745687. Epub 2008 May 27. Circulation. 2008. PMID: 18506005 Clinical Trial.
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. Dyke CK, et al. Among authors: lin m. Circulation. 2006 Dec 5;114(23):2490-7. doi: 10.1161/CIRCULATIONAHA.106.668434. Epub 2006 Nov 13. Circulation. 2006. PMID: 17101847 Clinical Trial.
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MPA, Chen CZ, Grosso MA, Mercuri MF, Segers A, Verhamme P, Vanassche T, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR. Medina A, et al. Among authors: lin m. Thromb Haemost. 2017 Dec;117(12):2406-2414. doi: 10.1160/TH17-05-0523. Epub 2017 Dec 6. Thromb Haemost. 2017. PMID: 29212128 Free PMC article. Clinical Trial.
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Moll F, Baumgartner I, Jaff M, Nwachuku C, Tangelder M, Ansel G, Adams G, Zeller T, Rundback J, Grosso M, Lin M, Mercur MF, Minar E; ePAD Investigators. Moll F, et al. Among authors: lin m. J Endovasc Ther. 2018 Apr;25(2):158-168. doi: 10.1177/1526602818760488. J Endovasc Ther. 2018. PMID: 29552984 Free PMC article. Clinical Trial.
16,771 results
You have reached the last available page of results. Please see the User Guide for more information.